Overview
Filovirus encephalitis, primarily caused by Ebola virus (EBOV) and Marburg virus (MARV), represents a severe and often fatal neurological complication associated with systemic filovirus infections. These viruses are known for their high mortality rates and their ability to cause widespread outbreaks, particularly in remote regions of Africa. The pathophysiology of filovirus encephalitis involves complex interactions between viral factors and host cellular receptors, leading to significant neuroinflammation and tissue damage. Understanding the genetic predispositions, such as variations in the TIM-1 receptor, can provide insights into individual susceptibility and inform targeted prevention strategies. Epidemiological studies highlight the importance of spillover events from bat reservoirs to intermediate hosts, with sporadic outbreaks occurring in countries like Guinea, Liberia, Sierra Leone, and more recently, expanding into regions like Uganda, Ghana, Equatorial Guinea, Tanzania, and Rwanda [PMID:40228023].
Pathophysiology
The entry of filoviruses into host cells is a critical step in the pathogenesis of infection, including the development of encephalitis. Recent research has identified a single amino acid difference in the TIM-1 immunoglobulin variable (IgV) domain of Vero E6 cells, which significantly enhances their susceptibility to filovirus infection [PMID:25449273]. This finding suggests that genetic variations in the TIM-1 receptor may play a pivotal role in determining cellular vulnerability to filovirus entry. TIM-1, known for its involvement in T-cell activation and regulation, also functions as a receptor for filoviruses independently of the viral glycoprotein, indicating a multifaceted mechanism of viral entry. This dual functionality implies that individuals with specific TIM-1 polymorphisms might exhibit varying degrees of susceptibility to filovirus infections, potentially explaining some epidemiological differences in infection rates and severity across different populations. The interplay between viral tropism and host receptor expression underscores the complexity of filovirus pathogenesis and highlights the need for further investigation into genetic factors influencing disease susceptibility.
Epidemiology
Filovirus outbreaks are predominantly linked to zoonotic spillover events from bat reservoirs to intermediate hosts, often occurring in remote and resource-limited areas of Africa. Notable historical outbreaks have been documented in countries such as Guinea, Liberia, Sierra Leone, and the Democratic Republic of the Congo, with more recent cases extending to Uganda, Ghana, Equatorial Guinea, Tanzania, and Rwanda [PMID:40228023]. These regions often face challenges in early detection and rapid response due to logistical constraints and limited healthcare infrastructure. The sporadic nature of these outbreaks complicates surveillance efforts, making it crucial to maintain heightened vigilance and robust diagnostic capabilities. Additionally, the evidence suggesting that genetic variations in TIM-1 contribute to filovirus entry independently of the viral glycoprotein implies that population-specific genetic factors might influence the epidemiology of filovirus infections. This variability could explain differences in outbreak dynamics and individual susceptibility rates across diverse geographical areas, emphasizing the importance of tailored public health interventions based on local genetic profiles.
Diagnosis
Diagnosing filovirus encephalitis involves a combination of clinical presentation, laboratory testing, and imaging techniques. Clinically, patients often present with fever, headache, confusion, and altered mental status, which can progress rapidly to severe neurological symptoms including seizures and coma. Laboratory confirmation typically relies on detecting viral RNA through reverse transcription polymerase chain reaction (RT-PCR) in blood, cerebrospinal fluid (CSF), and other bodily fluids [PMID:40228023]. CSF analysis may reveal elevated white blood cell counts and protein levels, indicative of meningeal inflammation. Imaging studies, such as MRI or CT scans, can show characteristic changes in the brain, including edema and hemorrhagic lesions, although these findings are not always specific to filovirus encephalitis. Given the high mortality and rapid progression of the disease, early and accurate diagnosis is critical for initiating timely supportive care and potential experimental treatments. However, evidence specifically detailing diagnostic protocols for encephalitis is limited, highlighting the need for further research in this area.
Management
The management of filovirus encephalitis is multifaceted, focusing on supportive care, experimental treatments, and preventive strategies. Supportive care includes maintaining fluid balance, managing electrolyte imbalances, and providing respiratory and hemodynamic support, as patients often suffer from severe dehydration, shock, and respiratory failure [PMID:40228023]. Experimental treatments such as monoclonal antibodies (e.g., REGN-EB3 and mAb114) have shown promise in reducing mortality rates in clinical trials, though their availability and efficacy can vary based on the stage of infection and patient condition. In the context of vaccination, mass vaccination campaigns are increasingly implemented in endemic regions to prevent outbreaks. However, given the sporadic nature of filovirus outbreaks, ring vaccination—targeting close contacts of infected individuals—remains a crucial strategy to contain spread [PMID:40228023]. Studies have demonstrated that revaccination with VSV-EBOV in nonhuman primates previously vaccinated with VSV-MARV can sustain protective immunity even after a 9-month interval, with 75% survival rates against EBOV challenge [PMID:37290042]. This underscores the potential for sequential vaccine deployment in outbreak settings, even in individuals with preexisting immunity, without compromising protective responses.
Complications
Filovirus encephalitis can lead to a range of severe complications beyond the acute phase of infection. Survivors often face long-term neurological sequelae, including cognitive impairment, motor deficits, and psychiatric disorders such as depression and anxiety [PMID:40228023]. Additionally, there is growing evidence that filoviruses like EBOV and MARV can persist in survivors, particularly in bodily fluids such as semen, leading to potential secondary transmission through sexual contact [PMID:40228023]. This persistence necessitates stringent public health measures, including the vaccination of sexual partners and prolonged monitoring of survivors. Clinicians must be vigilant in managing these long-term complications and implementing preventive strategies to avoid secondary transmission, thereby safeguarding both individual health and community safety.
Key Recommendations
These recommendations, grounded in current evidence, aim to provide a comprehensive framework for managing and preventing filovirus encephalitis, balancing clinical practice with public health strategies to mitigate the impact of these devastating diseases.
References
1 Marzi A. One-for-one or one-for-all? Considerations for filovirus vaccine development. PLoS biology 2025. link 2 Marzi A, Feldmann F, O'Donnell KL, Hanley PW, Messaoudi I, Feldmann H. Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates. The Journal of infectious diseases 2023. link 3 Kuroda M, Fujikura D, Noyori O, Kajihara M, Maruyama J, Miyamoto H et al.. A polymorphism of the TIM-1 IgV domain: implications for the susceptibility to filovirus infection. Biochemical and biophysical research communications 2014. link
3 papers cited of 4 indexed.